Literature DB >> 11918676

Characterization, expression and complex formation of the murine Fanconi anaemia gene product Fancg.

Henri J van de Vrugt1, Mireille Koomen, Mariska A D Berns, Yne de Vries, Martin A Rooimans, Laura van der Weel, Eric Blom, Jan de Groot, Rik J Schepers, Stacie Stone, Maureen E Hoatlin, Ngan Ching Cheng, Hans Joenje, Fré Arwert.   

Abstract

BACKGROUND: Fanconi anaemia (FA) is an autosomal recessive chromosomal instability disorder. Six distinct FA disease genes have been identified, the products of which function in an integrated pathway that is thought to support a nuclear caretaker function. Comparison of FA gene characteristics in different species may help to unravel the molecular function of the FA pathway.
RESULTS: We have cloned the murine homologue of the Fanconi anaemia complementation group G gene, FANCG/XRCC9. The murine Fancg protein shows an 83% similarity to the human protein sequence, and has a predicted molecular weight of 68.5 kDa. Expression of mouse Fancg in human FA-G lymphoblasts fully corrects their cross-linker hypersensitivity. At mRNA and protein levels we detected the co-expression of Fancg and Fanca in murine tissues. In addition, mouse Fancg and Fanca proteins co-purify by immunoprecipitation. Upon transfection into Fanca-deficient mouse embryonic fibroblasts EGFP-Fancg chimeric protein was detectable in the nucleus.
CONCLUSIONS: We identified a murine cDNA, Fancg, which cross-complements the cellular defect of human FA-G cells and thus represents a true homologue of human FANCG. Spleen, thymus and testis showed the highest Fancg expression levels. Although Fancg and Fanca are able to form a complex, this interaction is not required for Fancg to accumulate in the nuclear compartment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918676     DOI: 10.1046/j.1365-2443.2002.00518.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  7 in total

1.  Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance.

Authors:  James B Wilson; Eric Blom; Ryan Cunningham; Yuxuan Xiao; Gary M Kupfer; Nigel J Jones
Journal:  Mutat Res       Date:  2010-05-05       Impact factor: 2.433

2.  FANCL ubiquitinates β-catenin and enhances its nuclear function.

Authors:  Kim-Hien T Dao; Michael D Rotelli; Curtis L Petersen; Stefanie Kaech; Whitney D Nelson; Jane E Yates; Amy E Hanlon Newell; Susan B Olson; Brian J Druker; Grover C Bagby
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

3.  Embryonic lethality after combined inactivation of Fancd2 and Mlh1 in mice.

Authors:  Henri J van de Vrugt; Laura Eaton; Amy Hanlon Newell; Mushen Al-Dhalimy; R Michael Liskay; Susan B Olson; Markus Grompe
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

4.  Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.

Authors:  Petra van der Groep; Michael Hoelzel; Horst Buerger; Hans Joenje; Johan P de Winter; Paul J van Diest
Journal:  Breast Cancer Res Treat       Date:  2007-02-27       Impact factor: 4.872

5.  The cellular phenotype of Roberts syndrome fibroblasts as revealed by ectopic expression of ESCO2.

Authors:  Petra van der Lelij; Barbara C Godthelp; Wouter van Zon; Djoke van Gosliga; Anneke B Oostra; Jûrgen Steltenpool; Jan de Groot; Rik J Scheper; Rob M Wolthuis; Quinten Waisfisz; Firouz Darroudi; Hans Joenje; Johan P de Winter
Journal:  PLoS One       Date:  2009-09-07       Impact factor: 3.240

6.  Fanconi anemia genes are highly expressed in primitive CD34+ hematopoietic cells.

Authors:  Michel Aubé; Matthieu Lafrance; Isabelle Brodeur; Marie-Chantal Delisle; Madeleine Carreau
Journal:  BMC Blood Disord       Date:  2003-06-16

7.  Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair.

Authors:  Henri J van de Vrugt; Tim Harmsen; Joey Riepsaame; Georgina Alexantya; Saskia E van Mil; Yne de Vries; Rahmen Bin Ali; Ivo J Huijbers; Josephine C Dorsman; Rob M F Wolthuis; Hein Te Riele
Journal:  Sci Rep       Date:  2019-01-25       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.